KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Cash & Equivalents readings, the most recent being $1.7 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 67.78% to $1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 billion, a 67.78% increase, with the full-year FY2025 number at $1.7 billion, up 71.09% from a year prior.
  • Cash & Equivalents hit $1.7 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $1.7 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q1 2026 to a low of $534.1 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $968.7 million (2024), compared with a mean of $996.3 million.
  • Biggest five-year swings in Cash & Equivalents: fell 22.82% in 2022 and later soared 71.09% in 2025.
  • Alnylam Pharmaceuticals' Cash & Equivalents stood at $868.6 million in 2022, then fell by 6.43% to $812.7 million in 2023, then increased by 19.19% to $968.7 million in 2024, then soared by 71.09% to $1.7 billion in 2025, then rose by 3.23% to $1.7 billion in 2026.
  • The last three reported values for Cash & Equivalents were $1.7 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.5 billion (Q3 2025) per Business Quant data.